AmpliPhi Biosciences Corporation (APHB)

0.3201 -0.0059 (-1.81%)

IEX Real-Time Price

March 19, 2019 EST.

NYSE American : Healthcare

Prev Close 0.326

Price Open 0.35

Volume: 425,229

Avg Volume: 494,674

Market Cap: 10.34M

P/E Ratio -0.41

52 Wk Range 0.1539-1.37



APHB Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2019-02-28
31.85M
159,881
0.60
0.50%

2019-02-15
31.85M
213,730
0.89
0.67%

2019-01-31
31.85M
376,036
0.91
1.18%

2019-01-15
31.85M
375,055
0.65
1.18%




APHB Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-11-08
Q3 2018
N/A
-0.12 (2)
-0.10
0.02

2018-08-09
Q2 2018
N/A
-0.20 (2)
-0.19
0.01

2018-05-21
Q1 2018
N/A
-0.19 (1)
0.00
0.00

2018-05-15
Q1 2018
AMC
-0.19 (2)
-0.24
-0.05

News

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript) (2019-01-14 19:07 SeekingAlpha)

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O…

 


Statistics

Shares Outstanding: 32.29M

Top 15 Institution Percent: 6.80

Price To Sales: N/A

Price To Book: 1.54

Revenue: N/A

Gross Profit: N/A

Cash: N/A

Debt: N/A

Return On Assets: -83.61

Return On Equity: -122.86

Profit Margin: N/A

Price History

Beta: 2.79

50-day Moving Avg: 0.27

200-day Moving Avg: 0.64

YTD Change: 36.10

5-day Change: -2.44

1-month Change: 20.79

3-month Change: 75.21

6-month Change: -63.21

1-year Change: -79.21

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: AmpliPhi Biosciences Corporation

Exchange: NYSE American

Industry: Biotechnology

Sector: Healthcare

Website: http://www.ampliphibio.com

Ampliphi Biosciences Corp engages in discovery, development, and commercialization of novel phage therapeutics.